| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 22/11/2024 | 22:45 | GlobeNewswire Inc. | Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q | NASDAQ:OCEA | Ocean Biomedical Inc |
| 22/10/2024 | 22:45 | GlobeNewswire Inc. | Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter | NASDAQ:OCEA | Ocean Biomedical Inc |
| 01/10/2024 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses | NASDAQ:OCEA | Ocean Biomedical Inc |
| 27/08/2024 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms | NASDAQ:OCEA | Ocean Biomedical Inc |
| 23/08/2024 | 22:30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCEA | Ocean Biomedical Inc |
| 05/06/2024 | 13:01 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 | NASDAQ:OCEA | Ocean Biomedical Inc |
| 16/05/2024 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease | NASDAQ:OCEA | Ocean Biomedical Inc |
| 24/04/2024 | 22:51 | GlobeNewswire Inc. | Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K | NASDAQ:OCEA | Ocean Biomedical Inc |
| 28/03/2024 | 13:01 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL | NASDAQ:OCEA | Ocean Biomedical Inc |
| 29/02/2024 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting | NASDAQ:OCEA | Ocean Biomedical Inc |
| 14/02/2024 | 00:43 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:OCEA | Ocean Biomedical Inc |
| 05/12/2023 | 14:15 | GlobeNewswire Inc. | Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody | NASDAQ:OCEA | Ocean Biomedical Inc |
| 15/11/2023 | 12:20 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:OCEA | Ocean Biomedical Inc |
| 14/11/2023 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics | NASDAQ:OCEA | Ocean Biomedical Inc |
| 26/10/2023 | 11:30 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection | NASDAQ:OCEA | Ocean Biomedical Inc |
| 26/10/2023 | 11:30 | PR Newswire (US) | Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection | NASDAQ:OCEA | Ocean Biomedical Inc |
| 24/10/2023 | 12:30 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis | NASDAQ:OCEA | Ocean Biomedical Inc |
| 17/10/2023 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics | NASDAQ:OCEA | Ocean Biomedical Inc |
| 12/10/2023 | 14:01 | PR Newswire (US) | Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide | NASDAQ:OCEA | Ocean Biomedical Inc |
| 12/10/2023 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide | NASDAQ:OCEA | Ocean Biomedical Inc |
| 04/10/2023 | 22:56 | GlobeNewswire Inc. | Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund | NASDAQ:OCEA | Ocean Biomedical Inc |
| 04/10/2023 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million | NASDAQ:OCEA | Ocean Biomedical Inc |
| 03/10/2023 | 20:30 | GlobeNewswire Inc. | Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner | NASDAQ:OCEA | Ocean Biomedical Inc |
| 03/10/2023 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers | NASDAQ:OCEA | Ocean Biomedical Inc |
| 14/09/2023 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD. | NASDAQ:OCEA | Ocean Biomedical Inc |
| 29/08/2023 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S. | NASDAQ:OCEA | Ocean Biomedical Inc |
| 16/08/2023 | 23:10 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:OCEA | Ocean Biomedical Inc |
| 10/08/2023 | 14:01 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers | NASDAQ:OCEA | Ocean Biomedical Inc |
| 09/08/2023 | 14:31 | GlobeNewswire Inc. | Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis. | NASDAQ:OCEA | Ocean Biomedical Inc |
| 04/08/2023 | 23:15 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:OCEA | Ocean Biomedical Inc |